A settlement was reached with the defendants in the lawsuit filed on behalf of certain investors of Lipocine Inc (NASDAQ: LPCN) over alleged securities laws violations and a deadline to submit the settlement claim is upcoming on June 11, 2018 and NASDAQ: LPCN investors should contact the Shareholders Foundation.
San Diego, CA -- (SBWIRE) -- 06/06/2018 -- A deadline is coming up on June 11, 2018 in the settlement reached in the securities class action lawsuit filed on behalf of investors who purchased shares of Lipocine Inc (NASDAQ: LPCN) between June 30, 2015 and June 28, 2016.
Investors who purchased a significant amount of shares of Lipocine Inc (NASDAQ: LPCN) between June 30, 2015 and June 28, 2016, have certain options and should contact the Shareholders Foundation by email at email@example.com or call +1(858) 779 - 1554.
The settlement proof of claim form or detailed settlement notice for the settlement in the Lipocine Inc (NASDAQ: LPCN) Investor Securities Class Action Lawsuit can be downloaded at: http://shareholdersfoundation.com/case/lipocine-inc-nasdaq-lpcn-investor-securities-class-action-lawsuit-07012016
In order to submit a claim an investor has to submit the claim proof to the class action claim administrator in a timely manner. The deadline to submit the proof with the class administrator is June 11, 2018. The class action administrator for this case is Strategic Claims Services.
The lawsuit was originally filed in the U.S. District Court for the District of New Jersey over alleged violations of Federal Securities Laws by Lipocine Inc in connection with certain allegedly false and misleading statements made between June 30, 2015 and June 28, 2016. According to the complaint the plaintiff alleges on behalf of purchasers of Lipocine Inc (NASDAQ: LPCN) common shares between June 30, 2015 and June 28, 2016, that the defendants violated Federal Securities Laws. More specifically, the plaintiff claims that between June 30, 2015 and June 28, 2016 the defendants made allegedly false and/or misleading statements and/or failed to disclose that Lipocine Inc's filing of its New Drug Application to the U.S. Food and Drug Administration for LPCN 1021, Lipocine Inc's lead product candidate, contained deficiencies, and that as a result, defendants' statements about Lipocine Inc's business and operations were false and misleading and/or lacked a reasonable basis.
Those who purchased shares of Lipocine Inc (NASDAQ: LPCN) have certain options and should contact the Shareholders Foundation.
Shareholders Foundation, Inc.
3111 Camino Del Rio North - Suite 423
92108 San Diego
For more information on this press release visit:
Media Relations Contact
Email: Click to Email Michael Daniels